Nanoviricides (NNVC) Capital Expenditures (2010 - 2025)

Nanoviricides has disclosed Capital Expenditures across 15 years of filings, most recently posting -$1.0 for Q4 2025.

• In Q4 2025, Capital Expenditures changed N/A year-over-year to -$1.0; the TTM figure through Mar 2026 stood at $94516.0 (down 34.78% YoY), while the FY2025 annual figure was $56964.0, down 63.62% from the prior year.
• Capital Expenditures came in at -$1.0 for Q4 2025 at Nanoviricides, down from $84317.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $185350.0 in Q4 2021 to a low of -$1.0 in Q4 2025.
• Average Capital Expenditures over 5 years is $53838.9, with a median of $44985.5 recorded in 2022.
• Year-over-year, Capital Expenditures plunged 96.6% in 2023 and surged 3725.53% in 2024.
• Over 5 years, Capital Expenditures stood at $185350.0 in 2021, then slumped by 75.54% to $45339.0 in 2022, then sank by 87.93% to $5474.0 in 2023, then soared by 754.29% to $46764.0 in 2024, then sank by 100.0% to -$1.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$1.0 in Q4 2025, $84317.0 in Q3 2025, and $10200.0 in Q2 2025.